Tvardi Therapeutics, Inc. TVRD R2K

Healthcare · Biotechnology · United States

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Market & Price

Market Cap

$31.71M

Current Price

$3.38

High / Low (52W)

$42.98 / $2.85

Beta

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$1.55

Price to Book

2.19

P/S

EV/EBITDA

-0.23

Dividend Yield

Profitability & Returns

ROCE

-127.18%

ROE

ROA

-68.64%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.73

EPS (TTM)

$-0.27

Balance Sheet & Liquidity

Debt/Equity

1.20

Quick Ratio

2.22

Current Ratio

2.25

Debt

$174.00K

Total Assets

$32.07M

Current Assets

$31.54M

Working Capital

$20.50M

Ownership

Promoter Holding

34.64%

Chg in Prom Hold

FII / Inst Holding

28.93%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$6.90M

Total Revenue (TTM)

EBITDA

$-29.35M

Free Cash Flow

$-11.57M

Operating Cash Flow

$-21.67M

Shares Outstanding

9.38M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

3.78%

Revenue (YoY)

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Trading 92.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TVRD Tvardi Therapeutics, Inc. R2K	3.38	-	$31.71M	-	-127.18%	-	-	3.78%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	2.87M	5.06M	5.53M	4.38M	5.21M	5.79M	4.51M	8.09M	5.63M	9.27M	112.09M	1.94M	-	20.27M	4.79M	23.00M	10.81M	6.17M	6.93M	4.87M	2.13M	991.00K	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.57M	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.35M	8.87M	5.94M	7.59M	7.05M
Operating Income	-5.73M	-5.01M	-	-10.99M	-13.33M	-11.77M	-	-22.32M	-9.63M	-12.96M	-	-17.12M	-17.81M	-20.47M	-	-23.13M	-24.14M	-34.43M	-	-30.00M	-25.88M	-17.02M	-	-23.56M	-30.88M	-1.12M	-27.91M	-4.47M	-23.84M	-27.65M	-32.34M	-28.90M	-29.67M	-7.18M	-	-4.35M	-8.87M	-5.94M	-7.59M	-7.05M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.33M	-8.85M	-5.91M	-7.56M	-7.03M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.87M	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9.58M	4.17M	-5.53M	-7.28M	-6.80M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-5.68M	-4.79M	-9.53M	-10.69M	-13.07M	-11.54M	-21.97M	-22.20M	-9.30M	-12.44M	-14.18M	-16.77M	-17.19M	-19.40M	-20.65M	-21.96M	-22.96M	-32.84M	-28.61M	-28.92M	-25.07M	-16.51M	78.91M	-23.30M	-30.75M	-1.01M	-27.75M	-4.21M	-23.18M	-26.66M	-31.48M	-28.03M	-4.20M	-6.97M	-	-9.58M	4.17M	-5.53M	-7.28M	-6.80M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.62	-0.54	-0.35	1.59	-0.47	-0.61	-0.02	-0.52	-0.08	-0.43	-0.49	-0.58	-0.52	-20.24	-2.71	-	-3.72	-1.00	-0.59	-0.78	-0.73
R&D Expense	4.68M	5.58M	-	8.55M	10.76M	9.67M	-	20.84M	6.96M	9.15M	-	13.43M	17.00M	22.30M	-	23.61M	24.36M	35.99M	-	33.54M	26.11M	21.07M	-	19.13M	25.23M	15.51M	21.27M	19.91M	24.69M	24.33M	30.31M	25.45M	21.96M	6.53M	4.79M	3.11M	5.81M	3.60M	-	4.91M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	86.00K	911.00K	13.47M	19.89M	135.08M	23.03M	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	21.19M	18.66M	28.11M	26.75M
Operating Income	-6.24M	-237.00K	-18.07M	-25.19M	-58.40M	-59.48M	-77.38M	-111.68M	5.38M	-89.08M	-21.19M	-18.66M	-28.11M	-26.75M
EBITDA	-	-	-	-	-	-	-	-	-	-	-20.45M	-17.25M	-28.01M	-26.65M
Interest Expense	-	-	-	-	-	-	-	-	-	-	3.00K	0	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-20.54M	-17.35M	-29.40M	-18.21M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6.27M	-3.96M	-17.75M	-24.69M	-57.28M	-58.12M	-74.01M	-106.37M	8.41M	-88.44M	-20.54M	-17.35M	-29.40M	-18.21M
Diluted EPS	-	-	-	-	-	-	-2.06	-2.49	0.18	-1.74	-7.98	-6.74	-11.41	-3.26
R&D Expense	4.60M	8.69M	15.07M	21.22M	49.25M	48.52M	75.53M	113.82M	107.85M	82.70M	91.88M	108.51M	23.65M	18.01M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	3.78%
1 Year:	-

Stock Price Performance

1 Year:	-88.07%
6 Months:	-12.89%
3 Months:	-15.29%
1 Month:	+10.46%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	18.08M	55.93M	110.90M	63.83M	97.00M	190.82M	232.96M	271.16M	247.06M	45.10M	27.00M	35.20M	32.07M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	44.11M	26.16M	31.69M	31.54M
Cash & Equivalents	4.10M	1.12M	12.36M	52.66M	15.10M	12.09M	9.39M	15.08M	18.30M	31.68M	13.45M	21.49M	22.92M	31.61M	20.73M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	90.15M	89.06M	126.33M	11.13M
Current Liabilities	-	-	5.43M	3.40M	5.27M	11.53M	8.51M	40.45M	42.89M	18.48M	17.62M	4.28M	3.28M	10.37M	11.04M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	30.26M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	450.00K	368.00K	30.56M	201.00K
Total Equity	-52.06M	-58.13M	-54.08M	51.66M	105.04M	50.73M	86.78M	133.63M	186.71M	249.00M	227.52M	-45.05M	-62.06M	-91.13M	20.95M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	9.36M	9.36M	9.36M	9.38M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-47.38M	-54.83M	-22.30M	-109.22M	-5.49M	-60.09M	-17.87M	-21.04M	-18.30M	-23.50M
Investing Cash Flow	-	-	-	45.02M	-36.50M	-82.82M	-30.52M	-20.27M	-4.75M	-22.00M	22.47M	0	-10.08M
Financing Cash Flow	-	-	-	123.00K	87.92M	110.81M	142.60M	39.14M	46.61M	4.00K	2.00K	27.00M	22.70M
Capital Expenditure	-5.00K	-42.00K	-20.00K	-717.00K	-58.00K	-73.00K	-18.00K	-349.00K	-39.00K	-50.00K	-	-	-
Free Cash Flow	-	-	-	-48.10M	-54.88M	-22.37M	-109.24M	-5.84M	-60.13M	-17.92M	-21.04M	-18.30M	-23.50M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-39.86M	1.43M	8.70M	-10.88M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-67,907.0%	-6,529.6%	-574.5%	-561.6%	4.0%	-386.8%	-	-	-	-
Net Margin %	-	-	-	-	-66,604.7%	-6,380.4%	-549.5%	-534.9%	6.2%	-384.1%	-	-	-	-
ROE %	10.8%	7.3%	-34.3%	-23.5%	-112.9%	-67.0%	-55.4%	-57.0%	3.4%	-38.9%	45.6%	28.0%	32.3%	-87.0%
ROCE %	-	-1.9%	-34.4%	-23.8%	-111.7%	-67.2%	-51.5%	-58.8%	2.1%	-38.8%	-51.9%	-78.7%	-113.2%	-127.2%

Shareholding Pattern

Insiders

34.64%

Institutions

28.93%

Public Float

44.27%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Slate Path Capital, LP	7.51%	704.12K	$2.38M
2	Blackrock Inc.	4.14%	388.07K	$1.31M
3	Vanguard Capital Management LLC	3.67%	344.71K	$1.17M
4	American Financial Group Inc.	2.38%	223.66K	$755.97K
5	Geode Capital Management, LLC	1.94%	182.34K	$616.30K
6	Silvercrest Asset Management Group, LLC	1.08%	101.03K	$341.49K
7	State Street Corporation	1.04%	97.23K	$328.64K
8	Renaissance Technologies, LLC	0.98%	92.10K	$311.30K
9	Morgan Stanley	0.78%	72.89K	$246.38K
10	Duncan Williams Asset Management, LLC	0.67%	63.24K	$213.75K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TVRD

No recent headlines available.

TVRD · Healthcare